Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Generalized non-small cell lung cancer remains a therapeutic challenge. One of the modern approaches to treatment are also angiogenesis inhibitors.
The first successful molecule in this field was bevacizumab, which is used in adenocarcinomas in the first line therapy together with the platinum doublet. Nintedanib in combination with docetaxel then demonstrated effectiveness in the second line.
Likewise our case report confirms successful long-term stabilization of lung adenocarcinomas by this drug.